Medigene enters Phase I clinical development with its TCR-T immunotherapy MDG1021 in hematological cancers

NEXT STORY
BioAegis Therapeutics Completes Over-Subscribed Financing for COVID-19 Trial
PREV STORY
HTG EdgeSeq Technology Highlighted in Multiple Posters Presented by Pharma Partners at the 2020 American Association for Cancer Research Virtual Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat

author_avatar
NASDAQ Market News

Stemline Therapeutics Announces New England Journal of Medicine Publication of ELZONRIS (tagraxofusp) Pivotal Study Results

author_avatar
NASDAQ Market News

RedHill Biopharma Launches H. pylori Disease State Awareness Field Campaign Ahead of Talicia® Launch

author_avatar
NASDAQ Market News